2020
DOI: 10.1016/j.vaccine.2020.05.001
|View full text |Cite
|
Sign up to set email alerts
|

WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(7 citation statements)
references
References 8 publications
0
7
0
Order By: Relevance
“…Enterovirus A71 (EVA71) is a medically important member of the family Picornaviridae , being one of the main etiological agents of hand, foot, and mouth disease (HFMD). HFMD causes a substantial socioeconomic burden in regions of endemicity and, although this generally causes a mild self-limiting disease in children, outbreaks can be associated with neurological disease and death ( 1 , 2 ). Indeed, it appears that a combination of host and viral factors is associated with the likelihood of progressing to severe disease.…”
Section: Introductionmentioning
confidence: 99%
“…Enterovirus A71 (EVA71) is a medically important member of the family Picornaviridae , being one of the main etiological agents of hand, foot, and mouth disease (HFMD). HFMD causes a substantial socioeconomic burden in regions of endemicity and, although this generally causes a mild self-limiting disease in children, outbreaks can be associated with neurological disease and death ( 1 , 2 ). Indeed, it appears that a combination of host and viral factors is associated with the likelihood of progressing to severe disease.…”
Section: Introductionmentioning
confidence: 99%
“…Thus, it is necessary to supervise the antigenic evolution of EV-A71 and update the vaccine in time like influenza viruses. 42–47 Although the relationship between antibody titers and protection against reinfection remains unknown, high NtAb levels are always considered to indicate recent infection. In our study, the highest percentage of high level EV-A71 NtAbs was in the group of 10–19 and 20–29.…”
Section: Discussionmentioning
confidence: 99%
“…WHO organized a working group meeting in 2019 to develop WHO recommendations to assure the efficacy, safety and quality of EV-A71 vaccines. In view of its cross-reactivity with different genotypes of EV-A71, WHO recommendations suggested that the EV-A71-C4 a vaccine could be used worldwide [25].…”
Section: Inactivated Whole Ev-a71 Vaccinesmentioning
confidence: 99%
“…The purified, inactivated virus was able to induce neutralizing antibodies against EV-A71 in BALB/C mice. This prototype product will be further developed into an EV-A71 vaccine candidate [25].…”
Section: Inactivated Whole Ev-a71 Vaccinesmentioning
confidence: 99%